Date: 2013-01-08
Type of information: Joint-venture agreement
Compound: biotech medicinal products including ATryn® and FVIIa
Company: LFB, Laboratoire français du fractionnement des biotechnologies (France) Shin Poong (South Korea)
Therapeutic area: Hemtological diseases - Rare diseases
Type agreement: joint-venture
production
manufacturing
Action mechanism:
Disease:
Details: Shin Poong Pharmaceutical and Laboratoire français du Fractionnement et des Biotechnologies (LFB) have announced the signing of a term sheet for the establishment of a joint venture for the manufacturing and supply of biotech medicinal products. Both parties shall pursue to sign a definitive agreement during the first half of 2013 and set up a purification and fill and finish manufacturing facility in South Korea. The share ratio
shall be 55% for Shin Poong and 45% for LFB and the Joint Venture shall be governed by joint board members and management committee.
According to the term sheet, Joint Venture will initially focus on manufacturing and supplying the finished products of ATryn®, a recombinant form of human antithrombin that has received approvals from FDA and EMA to prevent thromboembolic events in hereditary antithrombin deficient patients, and FVIIa, arecombinant form of human factor VIIa to treat hemophilia currently under clinical development.
Joint Venture will have exclusive rights to supply those products to certain Asian countries and non-exclusive rights to supply other countries such as EU and USA through LFB and its regional partners.
Financial terms:
Latest news:
